Drug profile · INN
meropenem
VABOREM
meropenem (VABOREM) is a bacterial penicillin-binding protein inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — meropenem
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
meropenem (VABOREM) is a bacterial penicillin-binding protein inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is meropenem?
meropenem (VABOREM) is a bacterial penicillin-binding protein inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for meropenem?
VABOREM is a marketed brand name for meropenem. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of meropenem?
meropenem has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.